BRPI0510290A - partìculas ou agregado nanoparticulado compósito biocompatìvel, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partìculas ou agregados nanoparticulados ou de uma composição - Google Patents

partìculas ou agregado nanoparticulado compósito biocompatìvel, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partìculas ou agregados nanoparticulados ou de uma composição

Info

Publication number
BRPI0510290A
BRPI0510290A BRPI0510290-1A BRPI0510290A BRPI0510290A BR PI0510290 A BRPI0510290 A BR PI0510290A BR PI0510290 A BRPI0510290 A BR PI0510290A BR PI0510290 A BRPI0510290 A BR PI0510290A
Authority
BR
Brazil
Prior art keywords
particles
composition
nanoparticulate particles
aggregates
aggregate
Prior art date
Application number
BRPI0510290-1A
Other languages
English (en)
Inventor
Laurent Levy
Jean Francois Hochepied
Jeremy Balencie
Paras Nath Prasad
Earl Jim Bergey
Edouard Andre Panak
Abdel Kader Boussaha
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of BRPI0510290A publication Critical patent/BRPI0510290A/pt
Publication of BRPI0510290A8 publication Critical patent/BRPI0510290A8/pt
Publication of BRPI0510290B1 publication Critical patent/BRPI0510290B1/pt
Publication of BRPI0510290B8 publication Critical patent/BRPI0510290B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Paints Or Removers (AREA)

Abstract

PARTìCULA OU AGREGADO NANOPARTICULADO COMPóSITO BIOCOMPATìVEL, SEU PROCESSO DE PRODUçãO, COMPOSIçãO FARMACêUTICA OU DE DIAGNóSTICO E UTILIZAçãO DE PARTìCULAS OU AGREGADOS NANOPARTICULADOS OU DE UMA COMPOSIçãO A presente invenção refere-se a novas partículas ativáveis utilizáveis no domínio da saúde. Ela refere-se notadamente a partículas compósitas capazes de gerar radicais livres ou no calor sob excitação dos raios X, e suas utilizações em saúde, notadamente humana. As partículas da invenção compreendem um núcleo à base de compostos inorgânicos e, eventualmente, orgânicos, e elas podem ser ativadas in vivo, para marcar ou alterar células, tecidos ou órgãos. A invenção refere-se igualmente a processos de produção de tais partículas, assim como de composições farmacêuticas ou diagnósticos que as contenham.
BRPI0510290A 2004-05-10 2005-05-09 Partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição BRPI0510290B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0405036 2004-05-10
FR0405036A FR2869803B1 (fr) 2004-05-10 2004-05-10 Particules activables, preparation et utilisations
PCT/FR2005/001145 WO2005120590A1 (fr) 2004-05-10 2005-05-09 Particules activables, preparation et utilisations

Publications (4)

Publication Number Publication Date
BRPI0510290A true BRPI0510290A (pt) 2007-10-30
BRPI0510290A8 BRPI0510290A8 (pt) 2019-01-02
BRPI0510290B1 BRPI0510290B1 (pt) 2021-06-01
BRPI0510290B8 BRPI0510290B8 (pt) 2021-10-19

Family

ID=34945762

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510290A BRPI0510290B8 (pt) 2004-05-10 2005-05-09 Partícula ou agregado nanoparticulado compósito biocompatível, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partículas ou agregados nanoparticulados ou de uma composição

Country Status (24)

Country Link
US (2) US9162079B2 (pt)
EP (1) EP1744789B1 (pt)
JP (1) JP5150251B2 (pt)
KR (2) KR20120123731A (pt)
CN (1) CN100592921C (pt)
AT (1) ATE403444T1 (pt)
AU (1) AU2005251499B2 (pt)
BR (1) BRPI0510290B8 (pt)
CA (1) CA2564197C (pt)
CY (1) CY1108369T1 (pt)
DE (1) DE602005008731D1 (pt)
DK (1) DK1744789T3 (pt)
EA (1) EA010246B1 (pt)
ES (1) ES2312004T3 (pt)
FR (1) FR2869803B1 (pt)
HR (1) HRP20080534T3 (pt)
IL (1) IL178877A (pt)
MX (1) MXPA06013095A (pt)
PL (1) PL1744789T3 (pt)
PT (1) PT1744789E (pt)
RS (1) RS50615B (pt)
SI (1) SI1744789T1 (pt)
WO (1) WO2005120590A1 (pt)
ZA (1) ZA200610255B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
FR2877571B1 (fr) * 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
EP1819324B1 (en) * 2004-11-15 2016-10-26 Australian Nuclear Science & Technology Organisation Solid particles from controlled destabilisation of microemulsions
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
WO2007122956A1 (ja) * 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
EP1852107A1 (en) * 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
EP1920784A1 (en) * 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
US8951561B2 (en) 2007-08-06 2015-02-10 Duke University Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US8376013B2 (en) 2008-03-11 2013-02-19 Duke University Plasmonic assisted systems and methods for interior energy-activation from an exterior source
US9488916B2 (en) 2007-04-08 2016-11-08 Immunolight, Llc. Interior energy-activation of photo-reactive species inside a medium or body
FR2922106B1 (fr) * 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US8164074B2 (en) * 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
GB2453860B (en) * 2007-10-18 2011-03-16 Searete Llc Ionizing-radiation-responsive compositions,methods and systems
US8168958B2 (en) * 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8684898B2 (en) * 2007-10-18 2014-04-01 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090104113A1 (en) * 2007-10-18 2009-04-23 Searete Llc Ionizing-radiation-responsive compositions, methods, and systems
US8227204B2 (en) * 2007-10-18 2012-07-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) * 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8529426B2 (en) * 2007-10-18 2013-09-10 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US9907976B2 (en) 2011-07-08 2018-03-06 Immunolight, Llc Phosphors and scintillators for light stimulation within a medium
CA2906990A1 (en) * 2008-04-04 2009-10-08 Duke University Non-invasive systems and methods for in-situ photobiomodulation
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US8770203B2 (en) 2008-07-14 2014-07-08 Immunolight, Llc. Advanced methods and systems for treating cell proliferation disorders
BRPI0911715A2 (pt) 2008-07-31 2019-09-24 Alma Mater Studiorum - Universita' Di Bologna partículas ativas para aplicações bio-analíticas e métodos para sua preparação.
WO2010123993A1 (en) * 2009-04-21 2010-10-28 Tuan Vo-Dinh Non-invasive energy upconversion methods and systems for in-situ photobiomodulation
CN102870235B (zh) * 2009-11-10 2016-11-23 免疫之光有限责任公司 用于从包括用于上变频的射频、微波能量和磁感应源的各种能量源产生发射光的上下变频系统
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
WO2011140469A1 (en) 2010-05-06 2011-11-10 Zakaryae Fathi Adhesive bonding composition and method of use
US9572880B2 (en) 2010-08-27 2017-02-21 Sienna Biopharmaceuticals, Inc. Ultrasound delivery of nanoparticles
PT3213738T (pt) 2010-08-27 2020-03-31 Sebacia Inc Composições e métodos para modulação térmica direcionada
US9116246B2 (en) * 2011-04-07 2015-08-25 Stc.Unm Thermal neutron detectors based on gadolinium-containing nanoscintillators
JPWO2012153820A1 (ja) * 2011-05-12 2014-07-31 コニカミノルタ株式会社 Ｘ線吸収蛍光ナノ粒子
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2013035739A1 (ja) * 2011-09-05 2013-03-14 株式会社Ihi 温熱治療用材料、温熱治療用システム及び温熱治療方法
EA029635B1 (ru) 2011-12-16 2018-04-30 Нанобиотикс Применение наночастицы, включающей металлический материал, покрытый материалом оксида гафния, в онкологии и композиция, ее содержащая
AU2013329450B2 (en) 2012-10-11 2017-06-22 Coronado Aesthetics, Llc Silver nanoplate compositions and methods
US20160136304A1 (en) * 2013-06-20 2016-05-19 Nanobiotix Compositions and methods for use in oncology
EA201690050A1 (ru) * 2013-06-20 2016-05-31 Нанобиотикс Композиции и способы для применения в медицинской диагностике
FR3018451A1 (fr) * 2014-03-13 2015-09-18 Chromalys Nanoparticules pour leur utilisation dans la detection de tumeurs mobiles
US10780164B2 (en) * 2014-04-03 2020-09-22 The Governing Council Of The University Of Toronto Multifunctional nanoparticle compositions and uses thereof
CN110731961A (zh) 2014-10-14 2020-01-31 芝加哥大学 金属有机框架、药物制剂及其在制备药物中的用途
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US20180008733A1 (en) * 2015-01-08 2018-01-11 Purdue Research Foundation Non-toxic formulations of radio-luminescent nanoparticles for use as cancer radio-sensitizing agents
UA124572C2 (uk) 2015-05-28 2021-10-13 Нанобіотікс Наночастинки для застосування як терапевтичної вакцини
US9770688B2 (en) * 2015-10-22 2017-09-26 King Fahd University Of Petroleum And Minerals Si—Y nanocomposite membrane and methods of making and use thereof
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
CN110382010A (zh) 2016-12-08 2019-10-25 布里格姆妇女医院 铋-钆纳米颗粒
US10283476B2 (en) 2017-03-15 2019-05-07 Immunolight, Llc. Adhesive bonding composition and electronic components prepared from the same
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
EP3849613A2 (en) 2018-06-01 2021-07-21 Tae Life Sciences Biodegradable nanocarriers for neutron capture therapy and methods thereof
US20240000940A1 (en) * 2020-12-01 2024-01-04 Nanobiotix S.A. Porous, high-z and carbon-free particles as radioenhancers
CN112655715A (zh) * 2020-12-25 2021-04-16 杭州甜蜜按钮科技有限公司 一种哺乳期羊舍专用消毒剂的制备方法
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
EP4595983A1 (en) 2024-02-05 2025-08-06 BXTA Nanotherapy Limited Nanoparticles functionalised with a stabilising agent and a targeting agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985173A (en) * 1997-11-18 1999-11-16 Gray; Henry F. Phosphors having a semiconductor host surrounded by a shell
JP3490015B2 (ja) * 1999-03-11 2004-01-26 関西ティー・エル・オー株式会社 化学的耐久性に優れた放射性微小球及びその製造方法
AU3679801A (en) * 2000-02-08 2001-08-20 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
ATE320605T1 (de) * 2000-05-05 2006-04-15 Dotierte nanoteilchen als biolabel
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
CN1336174A (zh) * 2001-08-27 2002-02-20 董国臣 X线激发氧化锌卟啉化合物光动力作用的组合物抗癌光弹
EP1696957A2 (en) * 2003-12-17 2006-09-06 Philips Intellectual Property & Standards GmbH Radiation therapy and medical imaging using uv emitting nanoparticles
WO2005107818A2 (en) * 2004-04-30 2005-11-17 University Of Florida Nanoparticles and their use for multifunctional bioimaging
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same

Also Published As

Publication number Publication date
KR101234334B1 (ko) 2013-02-18
US9433800B2 (en) 2016-09-06
ES2312004T3 (es) 2009-02-16
IL178877A (en) 2010-12-30
EP1744789B1 (fr) 2008-08-06
CA2564197C (fr) 2013-05-07
US9162079B2 (en) 2015-10-20
IL178877A0 (en) 2007-03-08
BRPI0510290A8 (pt) 2019-01-02
FR2869803B1 (fr) 2006-07-28
AU2005251499A1 (en) 2005-12-22
SI1744789T1 (sl) 2008-10-31
MXPA06013095A (es) 2007-04-27
DE602005008731D1 (de) 2008-09-18
PT1744789E (pt) 2008-11-04
JP5150251B2 (ja) 2013-02-20
CN1950111A (zh) 2007-04-18
CY1108369T1 (el) 2014-02-12
AU2005251499B2 (en) 2010-06-10
PL1744789T3 (pl) 2009-01-30
EA010246B1 (ru) 2008-06-30
HK1099508A1 (zh) 2007-08-17
FR2869803A1 (fr) 2005-11-11
ATE403444T1 (de) 2008-08-15
BRPI0510290B1 (pt) 2021-06-01
DK1744789T3 (da) 2008-12-08
ZA200610255B (en) 2008-09-25
US20070217996A1 (en) 2007-09-20
KR20120123731A (ko) 2012-11-09
BRPI0510290B8 (pt) 2021-10-19
RS50615B (sr) 2010-06-30
KR20070014172A (ko) 2007-01-31
HRP20080534T3 (en) 2008-11-30
CA2564197A1 (fr) 2005-12-22
EP1744789A1 (fr) 2007-01-24
EA200602077A1 (ru) 2007-04-27
US20150238775A1 (en) 2015-08-27
JP2007536356A (ja) 2007-12-13
WO2005120590A1 (fr) 2005-12-22
CN100592921C (zh) 2010-03-03

Similar Documents

Publication Publication Date Title
BRPI0510290A (pt) partìculas ou agregado nanoparticulado compósito biocompatìvel, seu processo de produção, composição farmacêutica ou de diagnóstico e utilização de partìculas ou agregados nanoparticulados ou de uma composição
Khajuria et al. Accelerated bone regeneration by nitrogen-doped carbon dots functionalized with hydroxyapatite nanoparticles
Huja et al. Remodeling dynamics in the alveolar process in skeletally mature dogs
EP2041317A4 (en) METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
Gomes-Filho et al. Mineral trioxide aggregate but not light-cure mineral trioxide aggregate stimulated mineralization
BR112012024590A2 (pt) métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
ATE530168T1 (de) Magnetische nanoteilchen-zusammensetzungen und ihre verwendungen
Dalfino et al. Polycaprolactone/β-tricalcium phosphate composite scaffolds with advanced pore geometries promote Human mesenchymal stromal cells’ Osteogenic differentiation
Wang et al. Photocrosslinked gelatin methacryloyl/hyaluronic acid methacryloyl composite hydrogels loaded with bone morphogenetic protein 2-black phosphorus nanosheets for bone regeneration
BRPI0601751B8 (pt) compósito de colágeno e nanotubos de carbono e seu processo de obtenção
BRPI0606833A2 (pt) uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico
BR112012006267A2 (pt) processo para produzir partículas de substrato orgânico ligadas a nanopartículas ferromagnéticas comutáveis, partículas de substrato para diagnóstico, uso de nanopartículas ferromagnéticas comutáveis, e, medicamento para o tratamento de hipertermia no corpo humano ou animal
Lyu et al. Controlled Release of Growth Differentiation Factor 5 from Polyethylene Glycol-Stabilized Amorphous Calcium Phosphate Nanoparticle Electrospun Fibers to Promote Periodontal Bone Regeneration
Ellis Nanodentistry: The benefits of nanotechnology in dentistry and its impact on oral health
Alateya et al. The Effect of carbon quantum dots on the microhardness and the morphological characteristics of human dental enamel: in vitro study
Toulou Extrusion-Based 3D-Printed Quercetin Loaded Polycaprolactone–Tricalcium Phosphate Scaffold for Bone Tissue Engineering Applications
Sales Fabrico e caracterização mecânica de placas estabilizadoras de fraturas em material compósito polimérico
SRINIVASAN et al. Synthesis and Assessment of the Antimicrobial Efficacy of a Novel Graphene Oxide-Copper Oxide Nanocomposite Against Oral Pathogens: An In-vitro Study.
Wang et al. Rational Design of Lamellar Heterostructural Mg/PLLA Composite Membrane Enables Spatiotemporal‐Sequential Neuro‐Vascularized Bone Regeneration
Laviv et al. Island Osteoperiosteal Flap Vitality when Isolated from Basal Bone by Silicone Interposition: An Experimental Study in Rabbit Tibia.
ROY et al. To evaluate the osteogenesis and Osseointegration on titanium implants Surface treated with cissus Quadrangularis hydrogel: an in-vivo Animal study
Yeh et al. Poly-ε-caprolactone/multi-wall carbon nanotube composites as osteoinductive scaffolds for alveolar bone regeneration
BATUBARA et al. DIFFERENCES IN THE EFFECT OF APPLYING 6% AND 12% HYDROXYAPATITE PASTE FROM DUCK EGGSHELLS (ANAS PLATYRHYNCHOS) WITH CASEIN PHOSPHOPEPTIDE-AMORPHOUS CALCIUM PHOSPHATE (CPP-ACP) AS REMINERALIZING MATERIALS ON ENAMEL SURFACE HARDNESS (IN VITRO)
BRPI0514181A (pt) compostos orgánicos
UTAMA et al. THE CONTENT OF COMPOUND AND BIOACTIVE SUBSTANCE OF THE ROSELLA PETALS EXTRACT GEL TO ACCELERATE THE REMODELING PROCESS OF THE ALVEOLAR BONE

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/05/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE O DEFERIMENTO NOTIFICADO NA RPI NO 2626 DE 04/05/2021.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2630, QUANTO AO RELATORIO DESCRITIVO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2722 DE 07-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.